ReviewClinical kidney journal2023
Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN).
Review in Clinical kidney journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- A Review and Future Perspective on Renal Outcome Definitions in Lupus Nephritis.ACR open rheumatology · 2026Review
- Urinary ALCAM signatures define renal activity and therapeutic response in juvenile lupus nephritis.Pediatric rheumatology online journal · 2026Article
- Efficacy and safety of telitacicept as an add-on therapy for relapsing lupus nephritis: a retrospective cohort study.Frontiers in immunology · 2026Article
- Diagnostic utility of contrast-enhanced ultrasound parameters in classifying lupus nephritis.Clinical kidney journal · 2025Article
- Association between the CRP-TyG index and lupus nephritis risk.Biomolecules & biomedicine · 2025Article
- Aberrant Glycosylation of IgG in Children With Active Lupus Nephritis Alters Podocyte Metabolism and Causes Podocyte Injury.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Identification of urinary bacterial genes as biomarkers for non-invasive diagnosis of renal lupus.Biomarker research · 2025Article
- Heterogeneity of regional and national hospitalization burden of lupus nephritis and systemic lupus erythematous.Clinical kidney journal · 2025Article
- A Rare Case of Seronegative Lupus Nephritis Presenting as Immune Complex Diffuse Glomerulonephritis.Cureus · 2025Article
- Targeting Nanotherapeutics for Highly Efficient Diagnosis and Treatment of Systemic Lupus Erythematosus through Regulation of Immune Response.Small science · 2025Article
- Machine learning in lupus nephritis: bridging prediction models and clinical decision-making towards personalized nephrology.Frontiers in medicine · 2025Review
- Podocyte, tubular epithelial-immune cell interplay in the pathogenesis of lupus nephritis.Frontiers in immunology · 2025Review
- Lupus Nephritis from Pathogenesis to New Therapies: An Update.International journal of molecular sciences · 2024Review
- Comparison of Histomorphological Indices Between Adult and Pediatric Patients in Response to Induction Therapy.Cureus · 2024Article
- Article
- Article
- Factors influencing self-management behaviors in persons with lupus nephritis: A cross-sectional study.Belitung nursing journal · 2024Article
- Late-Onset Lupus Nephritis: Clinical-Epidemiological, Histological, Prognostic, and Therapeutic Implications: A Single-Center Experience from Northeastern Spain.Glomerular diseasesArticle
- Updates on Glomerular Diseases: A Summary of Inaugural GlomCon Hawaii 2024.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lupus nephritis (LN) is the most frequent serious manifestation of patients with systemic lupus erythematosus (SLE). Up to 60% of SLE patients develop LN, which has a significant impact on their quality of life and prognosis. Recent advances have improved the diagnostic approach to LN, and new drugs that block specific pathways and kidney damage progression have been developed. Several randomized and well-powered clinical trials have confirmed the efficacy of these agents in terms of proteinuria remission and preservation of kidney function in the medium and long term, with an acceptable safety profile and good tolerance. The combination of different therapies allows for reduction of the dose and duration of corticosteroids and other potentially toxic therapies and leads to an increase in the number of patients achieving complete remission of the disease. This consensus document carried out by the Spanish Group for the Study of Glomerular Diseases (GLOSEN) provides practical and updated recommendations, based on the best available evidence and clinical expertise of participating nephrologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.